3/28/2025TaiMed Announces Results from Phase 2a Data on Long-Acting HIV Mainten...

3/28/2025Recent Executive Moves

3/27/2025Big Pharma Faces Headwinds in China as Vaccine Sales Decline (PT)

3/27/2025China to Spur Innovation through New Reimbursement List (ThePharmaLett...

3/26/2025Merck Licenses Hengrui's Investigational Lp(a) Inhibitor HRS-5346

3/26/2025NMPA Holds 2025 National Drug Regulatory Policy and Law Conference

3/26/2025NMPA Issues Announcement on the Implementation of Chinese Pharmacopoei...

3/25/2025BrightGene Initiates Phase II Head-to-Head Study of AI-Designed BGM050...

3/25/2025Everest Announces FDA Clearance of IND Application for Tumor-Associate...

3/25/2025Eli Lilly Launches Lilly Gateway Laboratory in Beijing to Foster Innov...

3/25/2025Merck Group to Expand in China with Focus on AI-Powered Precision Medi...

3/25/2025China's BMI Fund Surpasses CNY16.5 Trillion with 11% Annual Growth

3/25/2025Expedition Therapeutics Secures Seed Funding to Bridge Chinese Innovat...

3/25/2025Growing Awareness and Expanding Treatment Options for Sleep Disorders ...

3/25/2025Hengrui and Elevar Face Second FDA Rejection for Liver Cancer Combo Th...

3/24/2025Elevation Oncology to Discontinue Development of CSPC-licensed EO-3021

3/24/2025HBM Enters into Global Strategic Deal with AstraZeneca for Next-Gen Th...

3/24/2025AstraZeneca Announces $2.5B Investment in China

3/24/2025CDE Seeks Public Comments on Draft ICH M11 Clinical Protocol Template

3/24/2025Heng Ren Partners Calls for $8.9B Cash Distribution from Sinovac and ...

3/21/2025Innovent and Hutchmed's FRUSICA-2 Study Achieves Primary Endpoint

3/21/2025Rhythm Pharma Regains Rights to Obesity Drug in China

3/21/2025Henlius' HER2-Targeting Antibody HLX22 Granted FDA Orphan Drug Designa...

3/21/2025Hengrui's Ivarmacitinib Secures First Approval in China for Ankylosing...

3/21/2025NHSA Releases Its 2024 Statistical Bulletin on Healthcare Security De...

3/21/2025Gilead's Trodelvy Receives Second Approval in China

3/21/2025Huadong Medicine's HDM1002 Advances to Phase III Clinical Trials

3/21/2025Junshi's Toripalimab Receives 11th Approval in China

3/21/2025NMPA Approves Hutchmed's Tazverik for r/r Follicular Lymphoma in China

3/21/2025Recent Executive Moves

Page:10/362 Total number of articles:10841: [First][<<] [8] [9] [10] [11] [12] [>>] [End]